Division of Novartis AG
Latest From IFM Tre
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and DGAT2 inhibitors. Their NASH trial collaboration is heading toward a Phase II launch in 2020.
Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
- Therapeutic Areas
- Hepatic (Liver)
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- North America
- Company Type
- Parent & Subsidiaries
- Novartis AG
- Senior Management
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.